Patient characteristics and treatment details before fistula presentation in patients with post-esophagectomy aero-digestive fistulas (ADF)
| N (%) . | Post-esophagectomy ADF (n = 22) . | |
|---|---|---|
| Clinical tumor stage | ||
| T1 | 4 (18.2) | |
| T2 | 1 (4.6) | |
| T3 | 17 (77.3) | |
| T4 | 0 (0) | |
| Clinical nodal stage | ||
| N0 | 11 (50.0) | |
| N1 | 8 (36.4) | |
| N2 | 3 (13.6) | |
| N3 | 0 (0) | |
| Tumor location | ||
| Proximal | 0 (0) | |
| Middle | 5 (22.7) | |
| Distal | 10 (45.5) | |
| Gastroesophageal junction | 7 (31.8) | |
| Histology | ||
| Esophageal squamous cell carcinoma | 7 (31.8) | |
| Esophageal adenocarcinoma | 14 (63.6) | |
| Missing | 1 | |
| Tumor directed treatment | ||
| Esophageal resection only | 8 (36.3) | |
| Neoadjuvant chemotherapy | 4 (18.2) | |
| Neoadjuvant chemoradiotherapy | 10 (45.5) | |
| Missing | 0 | |
| Anastomotic leakage diagnosed before ADF presentation, including treatment | ||
| Known anastomotic leakage before ADF presentation | ||
| Yes | 15 (68.2) | |
| No | 7 (31.8) | |
| Missing | 0 | |
| Number of esophageal stents per patient used for anastomotic leakage treatment | ||
| 1 | 3 (13.6) | |
| 2–4 | 2 (9.1) | |
| >4 | 0 (0) | |
| None | 17 (77.3) | |
| Missing | 0 | |
| Number of EsoSponges used per patient used for anastomotic leakage treatment | ||
| 1–2 | 4 (18.1) | |
| >2 | 1 (4.6) | |
| None | 17 (77.3) | |
| Missing | 0 | |
| Total number of days with EsoSponge | ||
| 0–10 | 1 (4.6) | |
| >10 | 4 (18.1) | |
| None | 17 (77.3) | |
| Missing | 0 | |
| N (%) . | Post-esophagectomy ADF (n = 22) . | |
|---|---|---|
| Clinical tumor stage | ||
| T1 | 4 (18.2) | |
| T2 | 1 (4.6) | |
| T3 | 17 (77.3) | |
| T4 | 0 (0) | |
| Clinical nodal stage | ||
| N0 | 11 (50.0) | |
| N1 | 8 (36.4) | |
| N2 | 3 (13.6) | |
| N3 | 0 (0) | |
| Tumor location | ||
| Proximal | 0 (0) | |
| Middle | 5 (22.7) | |
| Distal | 10 (45.5) | |
| Gastroesophageal junction | 7 (31.8) | |
| Histology | ||
| Esophageal squamous cell carcinoma | 7 (31.8) | |
| Esophageal adenocarcinoma | 14 (63.6) | |
| Missing | 1 | |
| Tumor directed treatment | ||
| Esophageal resection only | 8 (36.3) | |
| Neoadjuvant chemotherapy | 4 (18.2) | |
| Neoadjuvant chemoradiotherapy | 10 (45.5) | |
| Missing | 0 | |
| Anastomotic leakage diagnosed before ADF presentation, including treatment | ||
| Known anastomotic leakage before ADF presentation | ||
| Yes | 15 (68.2) | |
| No | 7 (31.8) | |
| Missing | 0 | |
| Number of esophageal stents per patient used for anastomotic leakage treatment | ||
| 1 | 3 (13.6) | |
| 2–4 | 2 (9.1) | |
| >4 | 0 (0) | |
| None | 17 (77.3) | |
| Missing | 0 | |
| Number of EsoSponges used per patient used for anastomotic leakage treatment | ||
| 1–2 | 4 (18.1) | |
| >2 | 1 (4.6) | |
| None | 17 (77.3) | |
| Missing | 0 | |
| Total number of days with EsoSponge | ||
| 0–10 | 1 (4.6) | |
| >10 | 4 (18.1) | |
| None | 17 (77.3) | |
| Missing | 0 | |
Patient characteristics and treatment details before fistula presentation in patients with post-esophagectomy aero-digestive fistulas (ADF)
| N (%) . | Post-esophagectomy ADF (n = 22) . | |
|---|---|---|
| Clinical tumor stage | ||
| T1 | 4 (18.2) | |
| T2 | 1 (4.6) | |
| T3 | 17 (77.3) | |
| T4 | 0 (0) | |
| Clinical nodal stage | ||
| N0 | 11 (50.0) | |
| N1 | 8 (36.4) | |
| N2 | 3 (13.6) | |
| N3 | 0 (0) | |
| Tumor location | ||
| Proximal | 0 (0) | |
| Middle | 5 (22.7) | |
| Distal | 10 (45.5) | |
| Gastroesophageal junction | 7 (31.8) | |
| Histology | ||
| Esophageal squamous cell carcinoma | 7 (31.8) | |
| Esophageal adenocarcinoma | 14 (63.6) | |
| Missing | 1 | |
| Tumor directed treatment | ||
| Esophageal resection only | 8 (36.3) | |
| Neoadjuvant chemotherapy | 4 (18.2) | |
| Neoadjuvant chemoradiotherapy | 10 (45.5) | |
| Missing | 0 | |
| Anastomotic leakage diagnosed before ADF presentation, including treatment | ||
| Known anastomotic leakage before ADF presentation | ||
| Yes | 15 (68.2) | |
| No | 7 (31.8) | |
| Missing | 0 | |
| Number of esophageal stents per patient used for anastomotic leakage treatment | ||
| 1 | 3 (13.6) | |
| 2–4 | 2 (9.1) | |
| >4 | 0 (0) | |
| None | 17 (77.3) | |
| Missing | 0 | |
| Number of EsoSponges used per patient used for anastomotic leakage treatment | ||
| 1–2 | 4 (18.1) | |
| >2 | 1 (4.6) | |
| None | 17 (77.3) | |
| Missing | 0 | |
| Total number of days with EsoSponge | ||
| 0–10 | 1 (4.6) | |
| >10 | 4 (18.1) | |
| None | 17 (77.3) | |
| Missing | 0 | |
| N (%) . | Post-esophagectomy ADF (n = 22) . | |
|---|---|---|
| Clinical tumor stage | ||
| T1 | 4 (18.2) | |
| T2 | 1 (4.6) | |
| T3 | 17 (77.3) | |
| T4 | 0 (0) | |
| Clinical nodal stage | ||
| N0 | 11 (50.0) | |
| N1 | 8 (36.4) | |
| N2 | 3 (13.6) | |
| N3 | 0 (0) | |
| Tumor location | ||
| Proximal | 0 (0) | |
| Middle | 5 (22.7) | |
| Distal | 10 (45.5) | |
| Gastroesophageal junction | 7 (31.8) | |
| Histology | ||
| Esophageal squamous cell carcinoma | 7 (31.8) | |
| Esophageal adenocarcinoma | 14 (63.6) | |
| Missing | 1 | |
| Tumor directed treatment | ||
| Esophageal resection only | 8 (36.3) | |
| Neoadjuvant chemotherapy | 4 (18.2) | |
| Neoadjuvant chemoradiotherapy | 10 (45.5) | |
| Missing | 0 | |
| Anastomotic leakage diagnosed before ADF presentation, including treatment | ||
| Known anastomotic leakage before ADF presentation | ||
| Yes | 15 (68.2) | |
| No | 7 (31.8) | |
| Missing | 0 | |
| Number of esophageal stents per patient used for anastomotic leakage treatment | ||
| 1 | 3 (13.6) | |
| 2–4 | 2 (9.1) | |
| >4 | 0 (0) | |
| None | 17 (77.3) | |
| Missing | 0 | |
| Number of EsoSponges used per patient used for anastomotic leakage treatment | ||
| 1–2 | 4 (18.1) | |
| >2 | 1 (4.6) | |
| None | 17 (77.3) | |
| Missing | 0 | |
| Total number of days with EsoSponge | ||
| 0–10 | 1 (4.6) | |
| >10 | 4 (18.1) | |
| None | 17 (77.3) | |
| Missing | 0 | |
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
